wikimedia
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
Graphs
1
Q38258948-B9045CE5-74EE-4194-A221-4D01020C1109
Q38258948-B9045CE5-74EE-4194-A221-4D01020C1109
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38258948-B9045CE5-74EE-4194-A221-4D01020C1109
Therapeutic strategies utilized in the setting of acquired resistance to EGFR tyrosine kinase inhibitors.
P2860
Q38258948-B9045CE5-74EE-4194-A221-4D01020C1109
BestRank
Statement
http://www.wikidata.org/entity/statement/Q38258948-B9045CE5-74EE-4194-A221-4D01020C1109
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
cc9c142cd1ceb55b1c504fef7cf3e1d706f8eb06
P2860
A phase 2 trial of dacomitinib (PF-00299804), an oral, irreversible pan-HER (human epidermal growth factor receptor) inhibitor, in patients with advanced non-small cell lung cancer after failure of prior chemotherapy and erlotinib.